T he mechanisms leading to brain injury as a result of whole-body ischemia and reperfusion (I/R) after cardiac arrest are complex. Hypoperfusion of the brain initiates a complex series of events, including excitotoxicity, oxidative stress, microvascular injury, blood-brain barrier dysfunction, and postischemic inflammation, ultimately leading to cell death of neurons, glia, and endothelial cells. Free oxygen radicals induce the production of proinflammatory cytokines by astrocytes and microglial cells, resulting in expression of adhesion molecules on the endothelial cell surface (1) . This leads to chemotaxis of activated leukocytes across the blood-spinal cord barrier and blood-brain barrier. Activation of the complement system further promotes the passage of neutrophils and monocytes to the brain tissue. So far, mild therapeutic hypothermia (MTH) is the only therapy applied that has been shown to be effective in increasing survival and decreasing morbidity in cardiac arrest patients (2, 3) . Several studies have demonstrated that hypothermia suppresses ischemia-induced proinflammation in traumatic brain injury (4) (5) (6) . The effect of MTH on the inflammatory response in patients after cardiac arrest has been poorly investigated and has resulted in conflicting data (7) (8) (9) .
Cardiac arrest and resuscitation represent a whole-body I/R syndrome with systemic activation of the innate immune system. This systemic inflammatory response may further contribute to the brain injury. At the same time, the postischemic brain inflammation can be transmitted to the peripheral immune system, thus contributing to the systemic inflammatory response (10) . Whereas early events are generally characterized by a proinflammatory response that contributes to the tissue damage, later events seem to be involved in cell repair and clearance of necrosis and apoptotic cell Objectives: The aim of this study was to simultaneously analyze the key components of the cerebral and systemic inflammatory response over time in cardiac arrest patients during mild therapeutic hypothermia and rewarming.
Design and Setting: Clinical observational study in a tertiary care university hospital.
Patients: Ten comatose patients after out-of-hospital cardiac arrest.
Interventions: All patients were cooled to 32-34°C for 24 hrs. After 24 hrs patients were passively rewarmed to normothermia.
Measurements and Main Results:
On admission and at 3, 6, 12, 24, and 48 hrs blood samples were taken from the arterial and jugular bulb catheter. Proinflammatory and anti-inflammatory cytokines and chemokines (interleukin-1ra, interleukin-1b, interleukin-6, interleukin-8, interleukin-10, interleukin-18, monocyte chemotactic protein-1, high-mobility group box-1 and tumor necrosis factor-a), complement activation products (C4d, Bb, C3a, and terminal complement complex), and the adhesion molecule soluble intercellular adhesion molecule were measured. Mean temperatures at the start of the study and at 12 and 24 hrs were 33.7  0.9°C, 32.7  0.92°C, and 34.5  1.5°C, respectively. Passive rewarming resulted in a temperature of 37.8  0.5°C at 48 hrs. The proinflammatory cytokine interleukin-6 increased from 12 to 24 hrs and returned to baseline levels after 48 hrs. In contrast, the chemokines interleukin-8 and monocyte chemotactic protein-1 stayed relatively high from the start and during the hypothermia period, decreasing to baseline levels after 48 hrs. The anti-inflammatory cytokines interleukin-10 and interleukin-1ra did not significantly change during mild therapeutic hypothermia and rewarming, although low values of interleukin-10 were observed after rewarming. A significant increase after rewarming was demonstrated on high-mobility group box-1 concentrations in the jugular bulb, whereas soluble intercellular adhesion molecule increased significantly during hypothermia and remained at this level after rewarming. Complement activation was increased on admission and decreased after induction of hypothermia, followed by a secondary increase during rewarming. No significant differences between any of the biomarkers were found between samples from the arterial and jugular bulb catheter.
Conclusions: Complement activation occurs during rewarming from mild therapeutic hypothermia after cardiac arrest. Interleukin-6 increased already from 12 to 24 hrs, concomitantly with a significant increase in the temperature seen during this period of mild therapeutic hypothermia. The optimal rate of rewarming is unknown. Additional clinical studies are needed to determine the optimal rewarming rate and strategy. (Crit Care Medbodies. The cross-talk between the cerebral and peripheral immune system in humans after whole-body I/R injury and the changes over time in the inflammatory response are largely unknown. The aim of this study was to describe the inflammatory response over time in patients treated with MTH after cardiac arrest.
MATERIALS AND METHODS
Study Population. We performed a prospective observational study of ten comatose patients successfully resuscitated from an out-of-hospital cardiac arrest treated with MTH. Because therapeutic MTH is an essential part of standard care, a normothermic control group was considered unethical. The local Institutional Review Board approved the protocol and written informed consent was obtained from the nearest relative. All patients of 18 yrs or older were eligible for the study if they met the following criteria: comatose (Glasgow Coma Scale score 6) after return of spontaneous circulation and primary cardiac rhythm, as documented by the paramedic team, was ventricular fibrillation. Patients were excluded if they were pregnant, received thrombolytic therapy, if there was a case of refractory cardiogenic shock, or if they had a life expectancy of ,24 hrs. Patients were also excluded if written informed consent could not be obtained within 4 hrs after admission to the intensive care unit. Times between collapse and return of spontaneous circulation, start of cooling, and start of the experiment were calculated based on data provided by the paramedic team.
Patient Management. All patients were admitted to the intensive care unit of a tertiary care university hospital in Nijmegen, the Netherlands. If necessary, a coronary angiogram and a percutaneous coronary intervention were performed before admission to the intensive care unit. In agreement with our local protocol, all patients were cooled to 32-34°C by rapid infusion of 30 mL/kg body weight of cold Ringer lactate at 4°C, followed by external cooling using two watercirculating blankets (Blanketroll II, Cincinatti Subzero; The Surgical Company, Amersfoort, the Netherlands). Temperature was measured continuously with a rectal temperature probe (YSI Incorporated 401, Van de Putte Medical, Nieuwegein, the Netherlands) and maintained at 32-34° C for 24 hrs, followed by passive rewarming to normothermia (defined as 37°C). All patients were sedated with midazolam or propofol or both and morphine during hypothermia. Sedation and analgesics were stopped as soon as the body temperature was 36.5°C. In case of shivering, patients were paralyzed using intravenous bolus injections of rocuronium.
All patients were intubated and mechanically ventilated aiming at a Pao 2 .75 mm Hg and Paco 2 between 34 and 41 mm Hg. The radial or femoral artery was cannulated for monitoring of blood pressure and sampling of arterial blood. A central venous catheter was inserted in the subclavian or jugular vein for administration of drugs and monitoring of central venous pressure. According to our local protocol, mean arterial blood pressure was maintained between 80 and 100 mm Hg, and diuresis was aimed at .0.5 mL/kg/hr. If necessary, patients were treated with volume infusion and dobutamine or (nor)epinephrine intravenously. According to our local protocol for postcardiac arrest patients, a 7-Fr singlelumen catheter was introduced into the left or right jugular bulb as described by Goetting and Preston (11) for monitoring of the cerebral oxygen extraction rate.
Serum concentrations of sodium, potassium, and magnesium were maintained within the normal range. All patients were treated with continuous insulin infusion therapy aiming at blood glucose levels between 4.4 and 6.1 mmol/L according to the protocol by Van den Berghe et al (12, 13) . Hemoglobin concentration was kept at 6.0 mmol/L. None of the patients were treated with anti-inflammatory drugs.
Data Collection and Blood Sampling. Demographic and prehospital data were collected on admission. Hemodynamic parameters, temperature, and Sao 2 were measured continuously. On admission and at 3, 6, 12, 24, and 48 hrs, blood samples were taken from the arterial and jugular bulb catheter. Blood samples were immediately centrifuged for 15 mins at 2000g at 4°C, and plasma was stored at -80°C until batch-wise analysis.
Measurements of Cytokines, Chemokines, and Adhesion Molecules. Interleukin (IL)-1 receptor antagonist (IL-1ra), IL-10, IL-18, monocyte chemotactic protein-1, and soluble intracellular adhesion molecule were determined using a simultaneous Luminex Assay according to the manufacturer's instructions (Bio-plex cytokine assay; BioRad, Hercules, CA). IL-1, IL-6, IL-8, and tumor necrosis factor- (TNF-) were determined using commercial enzyme-linked immunosorbent assays (BioRad) according to the manufacturer's instructions. High-mobility group box-1 (HMGB1) was determined using the HMGB1 enzyme-linked immunosorbent assay kit II (Shino-test, Shanghai, China).
Measurements of Complement Activation Products. The complement activation products C4d (classic and lectin pathway), Bb (alternative pathway), and C3a (common pathway) were measured using commercial enzyme-linked immunosorbent assay kits based on monoclonal antibodies directed against neoepitopes of the products and performed according to the manufacturer's instructions (Quidel, San Diego, CA). Soluble terminal complement complex (TCC; terminal pathway) was measured as described previously by Mollnes et al (14) using an enzyme-linked immunosorbent assay. Briefly, the coating C9 is incorporated into the TCC) and a biotinylated monoclonal anti-C6 antibody was used as detecting antibody. All samples were measured in duplicate. Values are expressed as arbitrary units per milliliter, related to a standard of human serum activated with zymosan, defined to contain 1000 arbitrary units/mL.
Statistical Analysis. Statistical analysis was performed using GraphPad Prism version 5.0 (GraphPad Software, La Jolla, CA). Data are presented as mean with sd or median with 25 th and 75 th percentiles in the boxand-whisker plots. The whiskers are drawn down to the minimum and up to the maximum. Changes over time were analyzed with repeated-measures test and the Wilcoxon matched pairs test. Differences between arterial and jugular bulb samples were analyzed using a two-way analysis of variance. A p , .05 was considered to indicate statistical significance.
RESULTS

Population
We studied ten comatose patients successfully resuscitated from an outof hospital cardiac arrest. Demographic data are shown in Table 1 . In all patients, ischemic cardiomyopathy was considered the underlying cause of the ventricular fibrillation. None of the patients required a coronary angiogram or percutaneous coronary intervention for myocardial infarction. At inclusion, none of the patients were in cardiogenic shock. All patients were treated with mild hypothermia according to our local protocol; in one patient the temperature was increased to 35°C after 18 hrs because of recurring arrhythmias. Five patients died in the intensive care unit, respectively, 2, 3, 3, 7, and 8 days after admission as a result of severe postanoxic brain damage. All five patients had a normal temperature at the time of death. One patient died of pneumosepsis in the hospital 8 days after discharge from the intensive care unit. There were no differences in delay between time collapse and return of spontaneous circulation, collapse and start of cooling, and collapse and start of experiment between survivors and nonsurvivors.
Clinical Data
Clinical data of the patients are shown in Table 1 . Between 12 hrs and 24 hrs, mean temperature increased significantly from 32.7°C to 34.5°C (p 5 .01). Three of ten patients received norepinephrine in maximal doses of 0.01, 0.04, and 0.19 µg/kg/min norepinephrine, respectively, during hypothermia. One patient was treated with epinephrine in a dosage of 0.13-0.25 µg/kg/min. Eight of ten patients received dobutamine in maximal doses ranging from 0.9-9.5 µg/kg/min dobutamine.
Measurements of Cytokines, Chemokines, Adhesion Molecules, and Complement Activation Products
The measured concentrations of IL-6, IL-8, monocyte chemotactic protein-1, IL-10, IL-1ra, soluble intracellular adhesion molecule, HMGB1, C4d, Bb, C3a, and TCC are demonstrated in Table 2 and Figures 1-4 . TNF- and IL-1 were below detection levels throughout the study period (,15.0 pg/L and ,8.0 pg/L, respectively). No differences in cytokine, chemokine, and adhesion molecule concentrations were found between arterial and jugular bulb samples at any time point during the study period. Although the complement activation products were consistently higher in jugular bulb samples, the difference between C4d, Bb, C3a, and TCC concentrations in arterial and jugular bulb samples was not statistically different.
DISCUSSION
In cardiac arrest survivors treated with MTH for 24 hrs, we observed an increase in IL-6 during the period of hypothermia, which could be explained by an intrinsic pyrogen response to body temperature below the hypothalamic set point. Serum complement levels were increased on presentation, suggesting endothelial activation declined during the period of hypothermia and increased again during rewarming. We also noted an increase in HMBG-1, a marker of I/R injury, during rewarming. Systemic and jugular bulb cytokine levels and complement activation were not significantly different. This is the first study to our knowledge investigating the systemic and cerebral inflammatory response in cardiac arrest patients treated with MTH. These data may be of importance because cerebral inflammation may partly explain the subsequent cerebral damage.
Our data conflict with the growing evidence for an isolated cerebral inflammatory response after cardiac arrest. Youngquist et al (15) recently demonstrated increased TNF- and IL-6 concentrations in the cerebrospinal fluid in patients after cardiac arrest. Meybohm et al (9) found a significant upregulation of messenger RNA expression of several cytokines (IL-1, IL-6, IL-10, TNF-, and soluble intracellular adhesion molecule-1) and a significant increase in IL-1 concentration in the cerebral cortex tissue of pigs that were subjected to cardiac arrest. Assuming intact blood-brain barriers after cardiac arrest, the increase in IL-1 may be the result of local cerebral synthesis rather than transport across the bloodbrain barrier (9, 16) . In contrast, Sharma et al (17) recently demonstrated that leakage of serum proteins into the brain microfluid environment occurs after induced cardiac arrest in a porcine model, which leads to brain edema formation, suggesting a breakdown of the blood-brain barriers. We believe that compartmentalized production of cytokines in the brain tissue may occur but could be masked by the large amount of cytokines produced systemically, potentially explaining the discrepancy between our findings and those discussed.
I/R triggers inflammation via direct effects on leukocytes, endothelium, and other tissues; so far, it has been associated with the acute release of cytokines, chemokines, and complement activation (18) (19) (20) (21) (22) (23) . A modest increase in temperature at the end of the hypothermia period was accompanied by a significant increase in IL-6, whereas IL-8 and monocyte chemotactic protein-1 barely changed. The increase in IL-6 concentration may be the result of the increase in body temperature or alternatively may cause the increase in body temperature. From the nature of this study, these effects are indistinguishable. Our results suggest that hypothermia as such does not prevent systemic proinflammatory cytokine, and chemokine responses. This, however, may depend on the degree of hypothermia, consistent with our finding of an increase in IL-6 concomitantly with a modest increase in temperature. After passive rewarming, IL-6, IL-8, and monocyte chemotactic protein-1 declined to baseline levels at 48 hrs. The antiinflammatory cytokines IL-10 and IL-1ra did not significantly change during hypothermia and rewarming, suggesting a stable anti-inflammatory response during the whole study period. Soluble intracellular adhesion molecule, mediating neutrophil adhesion to the endothelium and tissue translocation, like IL-6 increased from 12 to 24 hrs; however, in contrast to IL-6, soluble intracellular adhesion molecule levels remained stable after rewarming, suggesting a sustained endothelial cell activation after the I/R induced acute cytokine release and reactivation during rewarming. Altogether our data suggest a temporarily proinflammatory effect of rewarming in cardiac arrest patients treated with MTH, the effects of rewarming on the inflammatory response already have been observed in a number of clinical and experimental studies. Depending on the model and setting that was used, rewarming resulted in increased and decreased proinflammatory cytokine production (24) (25) (26) (27) (28) .
HMGB-1 is a nuclear factor released by necrotic cells and by activated immune cells, signaling via toll-like receptors and the receptors for advanced glycation end products. HMGB-1 acts as a potent "danger signal" initiating host defense or tissue repair and plays an important role in the pathogenesis of inflammatory diseases (29) . It has been proven to play an important role in the early event of I/R injury of the heart and in acute lung injury, resulting in the activation of proinflammatory pathways and additional cell injury (30, 31) . In our study, a significant increase after rewarming was demonstrated on HMGB- Activation of complement plays a critical role in I/R injury, leading to increased vascular permeability, activation of the coagulation cascade, free-radical production, and direct tissue damage (23) . Complement activation was initiated by the classic pathway and augmented by the alternative pathway, ultimately resulting in formation of the terminal complement complex. During normothermia, the anaphylatoxin C3a and the soluble membrane attack complex SC5b-9 (TCC) are increased during cardiopulmonary resuscitation and returned to baseline values within 48 hrs of return of spontaneous circulation (23) . Our study suggests that complement is activated at admission, consistent with the systemic I/R state of these patients. Notably, complement activation was relatively low during mild hypothermia. In fact, this is not surprising because complement activation is largely temperaturedependent. Changes in Bb were the most pronounced, pointing to the alternative pathway amplification loop being quantitatively responsible for most of the activation. It should be noted, however, that C4d also was increased at admission, reflecting a certain degree of classic or lectin pathway activation during ischemia reperfusion. Both these pathways have been shown to be candidates for such activation. Rewarming was followed by a secondary increase in complement components, significantly detected by the increase in TCC, which is known to be a sensitive indicator for complement activation (32) . These findings underscore that complement might be more susceptible to rewarming than the cytokine network.
Studies investigating the effect of MTH on the inflammatory response in patients after cardiac arrest have resulted in conflicting data. In a rat model, no differences over time of different cytokines and chemokines were demonstrated between hypothermic and normothermic rats, suggesting no specific role of systemic cytokines after cardiac arrest (7) . Upregulation of inflammatory cytokine and adhesion molecule expression in cerebral tissue was shown in pigs after cardiac arrest (9) . Hypothermia attenuated upregulation of messenger RNA expression compared with normothermic controls. Remarkably, in our study TNF- and IL-1 remained below detection limits. Adrie et al (18) , who studied cardiac arrest survivors treated without MTH, found detectable levels of TNF- in 33 of 61 (53%) patients; the presence of TNF- was significantly associated with a higher mortality rate. These and our data conflict with the findings of Fries et al (8) , who measured significantly elevated TNF- levels in the early phase after cardiopulmonary resuscitation in 71 patients during MTH. However, TNF- levels were lowest in the MTH group with a good neurologic outcome and hypothermia did not influence the course of elevated TNF- plasma levels. In contrast with our study, IL-6 plasma levels increased during MTH and were promptly reversed when patients were rewarmed.
The results of our study also may have been influenced by the use of catecholamines necessary to preserve a supramaximal blood pressure. The use of catecholamines is associated with decreased expression of TNF- and IL-6 and may have suppressed the inflammatory response and possibly may have resulted in an underestimation of the proinflammatory effect of rewarming in our patients (33) . Our study detected a transient proinflammatory effect during rewarming, particularly seen as increased complement activation, in cardiac arrest patients treated with MTH. Nevertheless, because of the absence of a normothermic control group (considered unethical), we cannot exclude a time effect in the regular course of the inflammatory response after cardiac arrest.
CONCLUSION
This is the first study to demonstrate changes in cytokines, complement activity, and markers of I/R injury during hypothermia and rewarming in patients after cardiac arrest. A modest increase in temperature during the late phase of MTH was associated with an increase in IL-6, whereas subsequent rewarming was accompanied by increased complement activation. The clinical importance of these changes in inflammatory parameters is still largely unknown and requires additional studies to determine the optimal duration of hypothermia and rewarming.
